Westfield Capital Management
IMVT icon

Westfield Capital Management’s Immunovant IMVT Stock Holding History

Westfield Capital Management’s Portfolio IMVT Stock Details IMVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$213K Buy
+8,581
New +$222K ﹤0.01% 249

Other funds holding IMVT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Westfield Capital Management's IMVT Position: Q1 2026 in Review

Westfield Capital Management opened a new position in Immunovant (IMVT) in Q1 2026: 8,581 shares worth $213K. The stake represents ﹤0.01% of the portfolio and ranks #249 among its holdings.

215 funds tracked by Wall St. Rank hold IMVT as of Q1 2026.

  • Westfield Capital Management held 8,581 shares of Immunovant worth $213K as of Q1 2026.
  • Immunovant was a new Westfield Capital Management position in Q1 2026.
  • Immunovant made up ﹤0.01% of Westfield Capital Management's portfolio in Q1 2026, its #249 holding.
  • 215 funds tracked by Wall St. Rank held Immunovant as of Q1 2026.

Based on Westfield Capital Management's 13F filing for Q1 2026, filed 11 May 2026.